Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPuS-4 long-term safety of avoralstat in hereditary angioedema
2015-003242-22Phase 3Terminated
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of avoralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Long-term safety and tolerability of avoralstat. Started Sep 2015; status: terminated.
02
Drugs
avoralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2015-003242-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003242-22.